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Background: Several studies have described an increased cyclooxygenase-2 (COX-2) expression in pancreatic
cancer, but the role of COX-2 in tumour development and progression is not clear. The aim of the present study
was to examine expression of COX-2 in cancer cells and stromal cells in pancreatic cancer specimens, and to
explore the role of PGE2 in pancreatic stellate cell proliferation and collagen synthesis.
Methods: Immunohistochemistry and immunofluorescence was performed on slides from whole sections of tissue
blocks using antibodies against COX-2 and α-smooth muscle actin (αSMA). Pancreatic stellate cells (PSC) were isolated
from surgically resected tumour tissue by the outgrowth method. Cells were used between passages 4 and 8.
Collagen synthesis was determined by [3H]-proline incorporation, or by enzyme immunoassay measurement of
collagen C-peptide. DNA synthesis was measured by incorporation of [3H]-thymidine in DNA. Cyclic AMP (cAMP)
was determined by radioimmunoassay. Collagen 1A1 mRNA was determined by RT-qPCR.
Results: Immunohistochemistry staining showed COX-2 in pancreatic carcinoma cells, but not in stromal cells.
All tumours showed positive staining for αSMA in the fibrotic stroma. Cultured PSC expressed COX-2, which
could be further induced by interleukin-1β (IL-1β), epidermal growth factor (EGF), thrombin, and PGE2, but not
by transforming growth factor-β1 (TGFβ). Indirect coculture with the adenocarcinoma cell line BxPC-3, but not
HPAFII or Panc-1, induced COX-2 expression in PSC. Treatment of PSC with PGE2 strongly stimulated cAMP accumulation,
mediated by EP2 receptors, and also stimulated phosphorylation of extracellular signal-regulated kinase (ERK).
Treatment of PSC with PGE2 or forskolin suppressed both TGFβ-stimulated collagen synthesis and PDGF-stimulated
DNA synthesis.
Conclusions: The present results show that COX-2 is mainly produced in carcinoma cells and suggest that the
cancer cells are the main source of PGE2 in pancreatic tumours. PGE2 exerts a suppressive effect on proliferation
and fibrogenesis in pancreatic stellate cells. These effects of PGE2 are mediated by the cAMP pathway and suggest
a role of EP2 receptors.
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Pancreatic adenocarcinoma is one of the most lethal
cancers of all solid malignancies with a 5 year survival
of less than 5% [1-3]. A particular feature of primary
pancreatic adenocarcinoma is the extensive fibrotic
stromal reaction known as tumour desmoplasia surround-
ing these tumours [4-6]. There is increasing evidence that
stromal cells are of major importance for tumour progres-
sion, by interacting in many ways with the malignant cells,
such as reciprocal paracrine proliferative stimulation and
angiogenesis, contributing to the early invasive growth
and metastasis of this tumour [6]. These observations
have raised the possibility that targeting the stromal cells
to interrupt paracrine stromal signalling mechanisms may
represent a new treatment strategy in pancreatic cancer.
Animal studies have also indicated that targeting the
tumour stroma of pancreatic cancer may improve drug
delivery [7-9].
Multiple lines of evidence suggest that pancreatic
stellate cells (PSC) have a major role in the development
of pancreatic cancer desmoplasia [4-6,10]. These cells,
which are normally quiescent cells in the pancreas, are
induced during pancreatic injury to undergo transform-
ation into a myofibroblast-like phenotype expressing alpha
smooth muscle actin (αSMA). Studies of human and rat
PSC in culture have identified a number of growth factors,
cytokines, and hormones as regulators of pancreatic
stellate cell activation [6]. Activation promotes PSC
proliferation, migration, and extracellular matrix (ECM)
deposition.
Overexpression of COX-2 has been reported in a
number of epithelial cancers, including pancreatic can-
cer [11-16]. Transgenic mouse models have suggested
that COX-2 overexpression in pancreatic ductal cells
contributes to pancreatic tumour development [17,18].
Upregulation of COX-2 leads to increased production
of prostaglandins, in particular PGE2. PGE2 may affect
both cancer cells and different stromal cells through its
effects on EP and FP receptors [19,20]. While EP2 and
EP4 receptors are Gs-coupled receptors that stimulate
adenylyl cyclase activity, EP3 receptors are Gi-coupled and
inhibit adenylyl cyclase activity. EP1 receptors elevate the
intracellular Ca2+-levels through mechanisms that may in-
volve both phospholipase C-dependent and independent
mechanisms [19-21], and FP receptors are Gq-coupled
and elevate intracellular Ca2+-levels [19,20]. In addition,
several of these receptors may signal via G protein-
independent mechanisms [22].
Fibroblasts may be stimulated by PGE2. Elevation of
the intracellular level of cAMP in response to PGE2 or
other stimuli in fibroblasts from different tissues has
been found to limit their proliferation, migration, and
collagen secretion, as well as the differentiation of fibro-
blasts to myofibroblasts [23-25]. These effects appear tobe mediated via EP2 and EP4 receptors. It has also been
reported that PGE2 may promote fibroblast proliferation
through activation of EP1, EP3, or FP signalling [26-29].
In hepatic stellate cells, PGE2 has been found to inhibit
transforming growth factor β (TGFβ)-mediated induction
of collagen mRNA [30], as well as proliferation induced
by platelet-derived growth factor (PDGF) or thrombin
[31,32]. However, the role of PGE2 in pancreatic fibrosis
is not well known. The aim of the present study was to
examine further the effects of PGE2 on pancreatic stellate
cell proliferation and collagen synthesis.
Methods
Patients
The study protocol and patient consent documents were
approved by the Regional Committee for Medical and
Health Research Ethics (REC South East, project num-
ber S-05081), and was in compliance with the Helsinki
Declaration. Written informed consent was obtained from
all study participants. The study included only adults.
Chemicals
Dulbecco’s Modified Eagle’s Medium, Ham’s F12 medium,
RPMI 1640 medium, glutamine, and Pen-Strep (10.000
U/ml) were obtained from Lonza (Verviers, Belgium).
HEPES, amphotericin, and heat-inactivated fetal bovine
serum (FBS) was purchased from Gibco (Grand Island,
NY, USA). Epidermal growth factor (EGF), adenosine 3’:5’-
cyclic monophosphate (cAMP), 3-isobutyl 1-methylxan-
thine (IBMX), L-ascorbic acid, and 3-aminopropionitrile
fumarate salt were obtained from Sigma-Aldrich (St.Louis,
MO, USA). Human platelet derived growth factor (PDGF),
recombinant human transforming growth factor-β (TGF-β),
and recombinant human interleukin-1β (IL-1β) were
obtained from R&D Systems Europe, Ltd (Abingdon,
England). Recombinant interleukin-1 receptor antagonist
(Anakinra®) was a gift from Swedish Orphan Biovitrum
AS, [6-3H] thymidine (20–30 Ci/mmol), [2,8-3H] adeno-
sine 3’,5’-cyclic phosphate ammonium salt (33.0 Ci/mmol),
and L-[2,3-3H] proline (55.0 Ci/mmol) were purchased
from PerkinElmer (Boston, MA, USA). L161982 (N-
[[4’-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)
phenyl]-4 H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]
sulfonyl]-3-methyl-2-thiophenecarboxamide, AH6809 (6-
isopropoxy-9-oxoxanthene-2carboxylic acid), and prosta-
glandin E2 (PGE2) were obtained from Cayman Chemical
(Ann Arbor, MI, USA). Procollagen Type I C-peptide
enzyme immunoassay kit was purchased from Takara
Bio Inc., Japan. All other chemicals were of analytical
quality. Antibodies against phosphorylated AktSer473,
total Akt, dually phosphorylated ERKThr202/Tyr204, and
GAPDH were obtained from Cell Signaling Technology
(Boston, MA, USA). Antibodies against COX-2 were
obtained from Cayman Chemical (Ann Arbor, MI, USA)
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USA). Anti-ERK antibody was from Upstate/Millipore
(Billerica, MA, USA). Antibodies against TGF-β receptor II
and PDGF receptor β were purchased from Cell Signaling
Technology (Boston, MA, USA). Antibody against EP2 re-
ceptor was obtained from Cayman Chemical (Ann Arbor,
MI, USA). Secondary antibodies were purchased from
Bio-Rad Laboratories (Hercules, CA, USA). Antibodies
against vimentin and cytokeratins 7 and 19 were provided
by DAKO (Glostrup, Denmark).
Isolation and culture of human pancreatic stellate cells
Human pancreatic stellate cells (PSC) were isolated by
the outgrowth method developed by Bachem et al. [33].
Pancreatic tissue blocks (100–150 mg) were obtained
during pancreatic surgery from patients with resectable
pancreatic head adenocarcinoma. Altogether, stellate cell
cultures were established from a total of 20 different pa-
tients. Briefly, the tissue blocks were cut using a razor
blade (0.5–1 mm3) and seeded in 10 cm2 uncoated culture
wells (6 per plate; 3–5 pieces per well) in a 1:1 (vol/vol)
mixture of Dulbecco’s modified Eagle medium (DMEM)
with Ham’s F12 medium, supplemented with l-glutamine
(2 mmol/L), 100 U/ml Pen-Strep, 2.5 μg/ml amphotericin,
and 10% FBS. Tissue blocks were cultured at 37°C in a 5%
CO2/air humidified atmosphere. Twenty-four hours after
seeding, the small tissue blocks were transferred to new
culture plates. Culture medium was changed every third
day. The PSCs grew out from the tissue blocks 7 to 10 days
later. The small tissue blocks were removed after 2–3
weeks. After reaching confluence, monolayers were
trypsinized and passaged 1:3. The purity of the cells was
assessed by morphology (most cells were stellate-like,
with long cytoplasmatic extensions; some were also spindle
shaped) and cytofilament staining of αSMA and vimentin.
None of the cells were positive for cytokeratins 7 or 19
(data not shown). All experiments were performed using
cell populations between passage 4 and 8.
Pancreatic adenocarcinoma cell lines
BxPC-3, HPAFII, and Panc-1 pancreatic adenocarcinoma
cell lines were purchased from ATCC (Manassas, VA,
USA). BxPC-3 cells were cultured in RPMI medium
containing 4.5 g/l glucose, HPAFII cells were cultured
in Dulbecco’s modified Eagle’s medium containing 1 g/l
glucose, and Panc-1 cells were cultured in Dulbecco’s
modified Eagle’s medium containing 4.5 g/l glucose.
The media were supplemented with glutamine (2 mM,
or 4 mM in the case of Panc-1), 100 U/ml Pen-Strep,
and 10% fetal bovine serum (FBS). Cells were plated in
Transwell® inserts (Corning Incorporated, Corning, NY,
USA) at a density of 100.000/cm2 in serum-containing
medium and cultured overnight. The next day, medium
was replaced with fresh, serum-free medium, and cellswere cultured overnight. The following day, the Transwells
were transferred to 12 well Costar plates containing stellate
cells in the lower compartment, and cells were cocultured
for 48 hours.
Coculture of pancreatic stellate cells with pancreatic
adenocarcinoma cell lines
Pancreatic stellate cells were plated at a density of
10.000 cells/cm2 in 12 well Costar plates with serum-
containing medium and cultured overnight. The following
day, medium was replaced with fresh, serum-free medium,
and cells were cultured overnight. The next day, the
serum-free medium was changed, and Transwells contain-
ing pancreatic adenocarcinoma cell lines were placed on
top. Cells were cocultured for 48 hours before harvesting
for immunoblotting.
Measurement of DNA synthesis
Pancreatic stellate cells were seeded into 12 well Costar
plates at a density of 10.000 cells/cm2 in serum-containing
medium and cultured overnight. On the following day,
medium was replaced with fresh, serum-free medium.
The next day, the serum-free medium was changed 30 mi-
nutes before addition of agonists. The cells were harvested
after pulsing for 6 hours with [3H]thymidine (18–24 hours
after addition of agonists), and DNA synthesis was mea-
sured as the amount of radioactivity incorporated into
DNA as previously described [34]. Briefly, medium was re-
moved, and cells were washed twice with 0.9% NaCl. The
cellular material was dissolved with 1 ml 0.5 N NaOH for
3 hours at 37°C, collected, mixed with 1 ml H2O, and
precipitated with 0.5 ml 50% trichloroacetic acid (TCA).
The acid-precipitable material was transferred to glass
fiber filters (GF/C Whatman, GE Healthcare, UK) and
washed twice with 5.0 ml 5% TCA, followed by liquid
scintillation counting of the filters in a Packard Tri-Carb
1900 TR liquid scintillation counter.
Measurement of collagen synthesis
Collagen synthesis was assessed by quantification of [3H]
proline incorporation into acetic acid-soluble proteins as
described by Jaster et al. [35]. Pancreatic stellate cells
were plated in 24 well Costar plates at a density of
10.000 cells/cm2 in serum-containing medium and cul-
tured overnight. The following day, medium was replaced
with fresh, serum-free medium. The next day, serum-free
medium was changed, and agonists and/or antagonist
were added. After 24 hours, the medium was replaced
with fresh serum-free medium containing 100 μg/ml as-
corbic acid, 100 μg/ml 3-aminopropionitrile, and 2 μCi/ml
[3H] proline, and fresh agonists were added. The reaction
was stopped 24 hours later, by addition of 50 μl/ml 10 N
acetic acid. After an overnight incubation at 4°C, culture
supernatants were transferred to microcentrifuge tubes,
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250 μl/ml 25% NaCl dissolved in 0.5 N acetic acid, and
incubated at 4°C for 30 minutes. Protein precipitates col-
lected by centrifugation (30 min, 10,000 g) were washed
twice with 5% NaCl, followed by dissolution of the pellet
in 0.5 N acetic acid. [3H] proline incorporation was de-
termined by liquid scintillation counting in a Packard
Tri-Carb 1900 TR scintillation counter. In initial experi-
ments, collagen synthesis was determined in parallell sam-
ples by measurement of procollagen type I C-peptide by
an enzyme immunoassay. The two methods yielded simi-
lar results (data not shown).
RNA extraction and real-time quantitative RT-qPCR
Pancreatic stellate cells were plated at a density of
10.000/cm2 in 20 cm2 wells in serum-containing medium
and cultured overnight. On the following day, medium
was replaced with serum-free medium. The next day the
medium was changed 30 minutes before agonists and/or
antagonist were added, as indicated. The cells were stimu-
lated for 24 hours. Total RNA was prepared from the
samples using RNA Easy Mini kit (Qiagen Inc, Valencia,
CA, USA) and cDNA was synthesized with SuperScript
III Reverse Transcriptase First-Strand cDNA Synthesis kit
according to the manufacturer’s protocol (InVitrogen,
Carlsbad, CA, USA). Quantitative PCR was performed
with Platinum SYBR Green Master Mix (Life Technologies,
Oslo, Norway) on 7900 Real-Time PCR system with 7900
System SDS 2.3 Software (Applied Biosystems) according
to the manufacturer’s protocol. Specific primers for colla-
gen 1A1 were: forward, 5’-TGACGTGATCTGTGACG
AGAC-3’ and reverse, 5’- GGTTTCTTGGTCGGTGG
GT −3’ (Life Technologies Oslo, Norway). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was utilized as
housekeeping gene, and specific primers were: forward,
5’-CCACCATGGAGAAGGCTGGGGCTC-3’ and reverse
5’-AGTGATGGCATGGACTGTGGTCAT3’ (Life Tech-
nologies, Oslo, Norway). The primers were designed using
Primer-BLAST [36]. All reactions were performed in trip-
licates including non-template controls. The results were
analyzed using the ΔΔCt method [37]. Results for collagen
1A1 were normalized to GAPDH, and controls were
assigned a value of 100%.
Cyclic AMP measurement
Pancreatic stellate cells were plated in 12 well Costar wells
at a density of 10.000 cells/cm2 in serum-containing
medium. On the following day, medium was replaced
with fresh, serum-free medium. The next day, medium
was replaced with Krebs-Ringer-Hepes buffer, pH 7.4,
containing 10 mM glucose. After preincubation for
30 minutes, cells were stimulated with PGE2 or forskolin as
indicated in the figure legends. The reaction was stopped
by removing the buffer and adding 5% TCA. cAMP in theneutralized TCA extract was determined by radioimmuno-
assay as previously described [38].
Immunoblotting
Aliquots with approximately 7000 cells (total cell lysate
prepared in Laemmli buffer) were electrophoresed on
12% (w/v) polyacrylamide gels (acrylamide: N’N’-bis-
methylene acrylamide 30:1). This was followed by protein
electrotransfer to nitrocellulose membranes and immuno-
blotting with antibodies against phospho-Akt, total Akt,
phospho ERK1/2, total ERK, COX-2, and GAPDH, respect-
ively. Immunoreactive bands were visualized with enhanced
chemiluminescence using LumiGLO (KPL Protein research
Products, Gaithersburg, MD, USA).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues from pancrea-
tectomy specimens were sectioned (3 μm), and dried at
60°C. Further processing was carried out in the Ventana
BenchMark Ultra machine (Ventana Medical Systems Inc.
(Tucson Arizona USA) according to the manufacturer’s
recommendations. Slides were incubated with monoclonal
anti-COX-2 antibodies (Thermo Fischer Scientific rabbit),
Universal Alkaline Phosphatase Red Detection Kit (Ultra
View 760–501) and a-SMA (Dako M.0851, DAB (Ultra
View 760–500). Finally, slides were counterstained with
haematoxylin, fixed, mounted and analyzed using an
inverted light microscope (Olympus, Center Valley, PA,
USA).
Immunofluorescence staining
Immunofluorescence staining was performed to examine
COX-2 expression in the tumour slides. Formalin-fixed,
paraffin-embedded tissues from pancreatectomy specimens
were sectioned (3 μm), dried at 60°C and hydrated. Slides
were incubated with monoclonal anti-COX-2 antibody
(Thermo sp21 rabbit) and anti-αSMA (DAKO 1A4 mouse)
for 30 min at room temperature in Ventana diluents. After
washing with PBS, slides were incubated with secondary
antibody conjugates (Alexa 555 anti-rabbit and Alexa 488
anti - mouse) in the dark for 1 hour in Dako diluents.
After three washes with PBS, slides were mounted in
VECTASHIELD containing DAPI (Vector Laboratories
Inc., Burlingame, CA, USA). Fixed cells were observed
under a fluorescence microscope.
Immunofluorescence staining was also performed on
the cultured pancreatic stellate cells. Cells were first
seeded into a Lab-Tek®II Chamber Slide™ System (Nunc
International, Naperville, IL, USA) and were cultured for
24 hours before they were fixed in 4% paraformaldehyde at
room temperature for 15 minutes. Cells were then washed
three times and incubated with 5% BSA for 30 minutes to
block non-specific binding. Slides were further processed
as describe for tumour tissue.
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Results are presented as mean ± standard error of the
mean (S.E.M). DNA and collagen synthesis data were ana-
lyzed by one-way ANOVA, and post test using Bonferroni
correction to compare groups, using GraphPad Prism
(version 5.01, GraphPad Software, San Diego, CA, USA).
Results
COX-2 expression in pancreatic cancer cells
COX-2 expression in tumour tissue from pancreatic cancer
was examined by double staining immunohistochemistry
for COX-2 and αSMA. The cancer cells generally exhibited
strong COX-2 staining (Figure 1A). We also found strong
αSMA staining in the tumour stroma, indicating the pres-
ence of activated PSC. However, we could not detect
double staining with COX-2 and αSMA in the stroma
(Figure 1A). This was examined further by immunofluor-
escence, which failed to detect any COX-2 staining in the
stroma (Figure 1B).
COX-2 expression in cultured human PSC
During culture of PSC, immunofluorescence staining in
different passages revealed perinuclear staining with
the COX-2 antibody in cells that were αSMA positive
(Figure 1C). The expression of COX-2, αSMA, EP2 recep-
tors, TGFβ receptors and PDGF receptors was found to
be stable as a function of cell passage number as assessed
by Western blotting (Figure 1D, 1E). Treatment of PSC
with EGF and PGE2 increased the expression of COX-2,
whereas treatment with TGFβ did not. This expression
pattern was observed in cells of both low and high passage
numbers (Figure 1F). PDGF had no significant effect.
Thrombin also induced COX-2 expression (data not
shown). Interleukin-1β (IL-1β) was found to be a potent
inducer of COX-2 expression, with maximal induction ob-
tained at 0.1 ng/ml (Figure 1G). Coculture of pancreatic
adenocarcinoma cell lines with pancreatic stellate cells
was previously found to upregulate COX-2 mRNA in both
stellate cells and adenocarcinoma cell lines [39]. We ex-
amined the effect of coculture of stellate cells with the
adenocarcinoma cell lines BxPC-3, Panc-1, and HPAFII.
Of these, only BxPC-3 cells induced COX-2 protein in the
stellate cells (Figure 2A). Furthermore, this effect was
abolished when the stellate cells were pretreated for one
hour with an IL-1 receptor antagonist (Figure 2B).
PGE2 stimulates EP2-mediated cAMP accumulation in PSC
PGE2 may affect cells through both EP and FP receptors.
Because fibroblasts from different tissues have been found
to express mainly EP2 and EP4 receptors [24,40,41], we
examined the effect of PGE2 on cAMP accumulation in
the stellate cells. When stellate cells were stimulated for
5 min with 100 μM PGE2 or 50 μM forskolin, a direct acti-
vator of adenylyl cyclase [42], in the presence of thephosphodiesterase inhibitor isobutylmethylxanthine (IBMX),
cAMP levels were elevated 16.8 ± 5.8-fold (mean ± S.E.M.)
above basal levels with PGE2, and 33.0 ± 11.7-fold above
basal with forskolin (n = 7). PGE2 induced a strong, dose-
dependent accumulation of cAMP, both in the absence
and presence of IBMX (Figure 3A). When cells were pre-
incubated with the EP4 receptor antagonist L-161982
[43], no significant inhibition of PGE2-stimulated cAMP
accumulation was observed. In contrast, AH6809, which
is commonly used as en EP2 receptors antagonist [19], al-
most abolished the cAMP response, suggesting that cAMP
accumulation in these cells is mediated mainly by EP2
receptors (Figure 3B).
PGE2 inhibits DNA synthesis in PSC
We next examined how PGE2 affected stellate cells prolifer-
ation. In agreement with previous studies [6,44,45], PDGF
strongly stimulated DNA synthesis (Figure 4A). Epidermal
growth factor (EGF) also stimulated DNA synthesis, al-
though to a lesser extent than PDGF, whereas TGFβ had
non-significant effect. (Figure 4A). In agreement with
these findings, PDGF and EGF, but not TGFβ, significantly
stimulated phosphorylation of both ERK and Akt in the
stellate cells (Figure 4C). Interestingly, PGE2, the FP select-
ive receptor agonist fluprostenol, and thrombin also stimu-
lated ERK phosphorylation in the stellate cells (Figure 4D),
while they did not induce Akt phosphorylation (data not
shown). The effect of PGE2 and fluprostenol on ERK
phosphorylation did not seem to involve cAMP, since
forskolin did not stimulate ERK phosphorylation.
In human hepatic stellate cells several growth-stimulatory
agents, including PDGF and thrombin, stimulate an acute
PGE2 production, as well as a delayed induction of COX-2,
and pretreatment with a COX inhibitor enhances their
growth stimulatory effect [31]. We examined the effect of
pretreatment with indomethacin on PDGF-stimulated
DNA synthesis in the pancreatic stellate cells. These ex-
periments showed that pretreatment with indomethacin
did not affect PDGF-stimulated DNA synthesis in the
pancreatic stellate cells (Figure 4B).
Treating the stellate cells with PGE2 did not significantly
affect the basal DNA synthesis, but attenuated PDGF-
stimulated DNA synthesis. PGE2 exerted an inhibitory
effect, which was significant at a concentration of 1 μM
(Figure 5A). This effect was mimicked by forskolin
(Figure 5B). cAMP levels were elevated above the basal
level for at least 60 minutes following stimulation with
PGE2 (Figure 5C) or forskolin (Figure 5D). Neither flu-
prostenol nor thrombin had any effect on DNA synthesis,
alone or in combination with PDGF (data not shown).
PGE2 inhibits collagen synthesis in PSC
In agreement with previous findings [6,45,46] treating
the stellate cells with TGFβ enhanced collagen synthesis,
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Figure 1 (See legend on next page.)
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Figure 1 COX-2 expression in formalin-fixed, paraffin-embedded tumour tissue from pancreatic cancer and isolated pancreatic stellate
cells. A. Immunohistochemistry of COX-2 expression in tumour tissue from pancreatic cancer. COX-2 positive cells - red colour, fibrotic stroma
αSMA positive - brown colour. B. Immunofluorescence of COX-2 expression in tumour tissue from pancreatic cancer. COX-2 positive cells - red
colour, stroma αSMA positive - green colour. C. Immunofluorescence staining of cultured pancreatic stellate cells, passage five; COX-2 positive
cells - red colour, αSMA positive cells - green colour, nucleus -blue colour. D. Expression of COX-2 and αSMA in different cell passage numbers.
E. Expression of EP2 receptors, TGFβ receptors and PDGF receptors in two different cell passages F. Induction of COX-2 protein by EGF (10 nM),
TGFβ (10 ng/ml), PGE2 (10 uM), and PDGF (10 ng/ml) in two different cell passages. Cells in serum-free medium were stimulated with agonists for
24 hours before cells were harvested and lysates examined by Western blots as described in Methods. Results are from one representative
experiment of four. G. Concentration dependent induction of COX-2 protein by IL-1β. Cells were stimulated in serum-free medium for 24 hours.
Results are from one typical experiment of three.
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synthesis (Figure 6A). In agreement with the lack of in-
duction of COX-2 by TGFβ in the stellate cells, pretreat-
ment with indomethacin did not affect TGFβ-induced
collagen synthesis (Figure 6B). Both PGE2 and forskolin
inhibited TGFβ-stimulated collagen synthesis, suggesting
that this was a cAMP-mediated effect (Figure 7A, B, C).
While we were preparing this manuscript, Charo et al.
reported that PGE2 stimulated the mRNA expression
of collagen 1A1 in an immortalized human pancreatic
stellate cell line [40]. To examine this further, RNA
was extracted from cultured pancreatic stellate cells and
assessed for elevated gene expression of collagen 1A1 by
real time RT-qPCR. While TGFβ increased gene expres-
sion, PGE2 alone showed a slight inhibitory effect, and sig-
nificantly attenuated TGFβ-stimulated increase in geneGAPDH
COX-2
Control Panc-1 HPAFII BxPc-3
GAPDH
COX-2
Control BxPc-3
BxPc-3
+Il-1Ra
A.
B.
Figure 2 Induction of COX-2 protein in pancreatic stellate cells
by indirect coculture with pancreatic adenocarcinoma cell lines.
A. Effect of coculture with Panc-1, HPAFII, and BxPC-3 cells. Cells
were cocultured in serum-free medium for 48 hours, before harvesting
and analysis by Western blots as described in Methods. Results are
from one typical of three experiments. B. Inhibition of COX-2 induction
by coculture with BxPC-3 cells when stellate cells were pretreated with
IL-1 receptor antagonist (1 μg/ml) for 1 hour before coculture for
48 hours. Results are from one typical of four experiments.expression of collagen 1A1 at a concentration of 1 μM
(Figures 7D, 7E). Since PGE2 might elevate cAMP levels
through EP2 or EP4 receptors, we examined the effect of
EP2 and EP4 receptor antagonists on collagen synthesis.
We found that the EP4 receptor antagonist L161982
did not abrogate the effect of PGE2 on TGFβ-induced
collagen synthesis (Figure 7F) whereas results with the
EP2 receptor antagonist AH 6809 were not conclusive
(data not shown).
Discussion
In the present study we have demonstrated that PGE2
inhibits both collagen and DNA synthesis in human
pancreatic stellate cells from pancreatic adenocarcinoma.
These effects are mediated by increased cAMP production.
It is well known that in fibroblasts from lung and other tis-
sues, PGE2 inhibits proliferation by activating Gs-coupled
EP2 and/or EP4 receptors [23-25,41,47,48]. Since EP4 in-
hibition affected neither the cAMP response nor the effect
on collagen synthesis by PGE2 in our study, it is most likely
that EP2 receptors mediate these inhibitory effects of PGE2
on cAMP and collagen synthesis. However, due to incon-
clusive results with the EP2 receptor antagonist, these
mechanisms require further experimental confirmation.
In human hepatic stellate cells, thrombin and PDGF
stimulate the release of PGE2, which exerts an inhibitory
effect on DNA synthesis induced by PDGF and thrombin
[31]. However, PGE2 appeared to mediate the mitogenic
effect of EGF in BALB/c 3 T3 cells, and of PDGF in Swiss
3 T3 cells [49,50]. In our study, EGF, PGE2 and thrombin,
but not PDGF, consistently induced COX-2 protein expres-
sion in the stellate cells.
Pretreatment of the cells with indomethacin did not
affect PDGF-stimulated DNA synthesis, suggesting that
COX-2 induction and PGE2 production neither mediated
nor modulated PDGF-stimulated DNA synthesis. While
we did not measure production of PGE2, studies in various
cells, including pancreatic stellate cells [40], indicate that
levels are in the nanomolar range. We did not detect an
effect of PGE2 on DNA synthesis in the stellate cells when
it was added alone, however, PGE2, as well as forskolin,
inhibited PDGF-stimulated DNA synthesis, suggesting
that this effect was mediated by cAMP. This is in contrast
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http://www.biomedcentral.com/1471-2407/14/413to findings in rat pancreatic stellate cells, where treatment
of the cells with conditioned medium from the Panc-1
adenocarcinoma cell line induced COX-2 expression and
stimulated DNA synthesis [51]. Furthermore, inhibition of
COX-2 activity with the COX-2 specific inhibitor NS-398
attenuated DNA synthesis in the rat stellate cells, albeit at
high concentrations of the inhibitor, which may lead to
nonspecific effects. Thus, at high concentrations of
NS-398, inhibition of DNA synthesis has been reported
in COX-2 expressing cell lines as well as in cell lines
without COX-2 expression [52-54].
Pancreatic stellate cells are believed to be essential in
the development of fibrosis associated with chronic
pancreatitis and pancreatic cancer [4-6,10]. However,
the role of PGE2 in pancreatic fibrosis is unknown.
TGFβ has been found to induce COX-2, which attenuates
the profibrotic effect of TGFβ, in lung fibroblasts and hep-
atic stellate cells [30,48], and exogenous addition of PGE2
inhibited TGFβ-induced collagen expression in hepatic
stellate cells [30]. However, we found no induction of
COX-2 by TGFβ in the pancreatic stellate cells, and prein-
cubation of the cells with indomethacin did not affect
TGFβ-stimulated collagen synthesis. In the lung, PGE2
has been found to inhibit collagen synthesis by activating
EP2 receptors and stimulating cAMP accumulation. In pa-
tients with idiopathic pulmonary fibrosis, lung fibroblasts
display a diminished capacity to express COX-2 and to
synthesize PGE2. This results in decreased levels of PGE2
and excessive fibroblast activation with massive fibrosis
[41,47,48]. Our findings in the pancreatic stellate cells are
consistent with these studies. Treatment with PGE2, as
well as forskolin, suppressed the increase in collagen
synthesis stimulated by TGFβ, suggesting that this effect
was mediated by cAMP. Our observations are thus in
disagreement with findings in an immortalized humanpancreatic stellate cell line, where 100 nM PGE2 was
found to induce mRNA of collagen 1A1 as well as other
structural genes involved in extracellular matrix forma-
tion [40]. We therefore examined the effect of PGE2 in
our stellate cells, and found no evidence of collagen
1A1 mRNA induction. Rather, PGE2 (1 μM) attenuated
the TGFβ-induced expression of collagen 1A1, which is
in agreement with our findings of an inhibitory effect of
PGE2 on collagen synthesis. The possibility that immor-
talized pancreatic stellate cells behave differently from
primary cell lines needs consideration. Interestingly, the
effects of PGE2 on immortalized stellate cells were me-
diated by activation of EP4 receptors [40]. We have
found no evidence of EP4 receptor involvement in the
cAMP response in our primary stellate cells, however, we
can presently not exclude the possibility that EP4 recep-
tors signal via G protein-independent pathways [22].
We observed that PGE2 stimulated ERK phosphorylation
in the stellate cells. This effect was mimicked by thrombin
and the FP selective agonist fluprostenol, but not by for-
skolin, suggesting that it was a cAMP-independent effect.
Thus, the stellate cells may express other EP receptors or
FP receptors that mediate this effect. PGE2 has been
reported to stimulate fibroblast proliferation through
activation of EP1, EP3, or FP signalling in lung and cardiac
fibroblasts, as well as in NIH 3 T3 cells [26-29]. If other
prostaglandin receptors could stimulate proliferation of
pancreatic stellate cells, the inhibitory effect of cAMP in-
duced by EP2 receptors, appear to suppress these effects.
It is notable that the inhibitory effect of PGE2 on collagen
and DNA synthesis was only significant at a concentration
of 1 μM, whereas in lung fibroblasts effects have been
observed at concentrations as low as 10 nM [41]. In a
comparative study of fibroblasts from lung and gingiva,
it was observed that stimulation with PGE2 resulted in
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http://www.biomedcentral.com/1471-2407/14/413less cAMP accumulation in gingival fibroblasts than in
lung fibroblasts [55]. Furthermore, EP3 receptor activa-
tion induced phosphorylation of c-Jun NH2-terminal
kinase (JNK), which also mediated TGFβ-stimulated fi-
brosis. Thus, simultaneous EP3 receptor activation
might reduce EP2-stimulated cAMP accumulation and
blunt the inhibitory effect on DNA and collagen synthe-
sis. Further studies, using subtype-specific agonists, or
knockdown of prostaglandin receptors, are required toexplore the role of other prostaglandin receptors on
proliferation and fibrosis in the stellate cells.
Several previous studies have demonstrated that COX-2
is overexpressed in most human pancreatic cancers
[12-16,56-60]. However, only a few publications have
addressed COX-2 expression in pancreatic stellate cells
and they reported no detectable COX-2 expression in
the stroma [16,60]. In our study, immunohistochemical
analysis carried out with a specific monoclonal antibody
D
N
A
 s
yn
th
es
is
, %
 o
f c
o
n
tr
o
l
0
100
200
300
Control PGE210-8M PGE210-7M PGE210-6M
PDGF
Control
D
N
A
 s
yn
th
es
is
, %
 o
f c
on
tr
ol
0
100
200
300
400
Control
PDGF
Control Forskolin 
Control
PGE2
cA
M
P, 
pm
ol
/m
g 
pr
ot
ei
n
0
50
100
150
200
0 5 15 30 45 60
Time, min
Control
Forskolin
cA
M
P, 
pm
ol
/m
g 
pr
ot
ei
n
0
50
100
150
200
0 5 15 30 45 60
Time, min
A. B.
C. D.
*
**
*
**
10-6M
Figure 5 Effect of PGE2 and forskolin on DNA synthesis and cAMP accumulation. A. Effect of increasing concentrations of PGE2 on PDGF-stimulated
DNA synthesis. Results are presented as mean ± S.E.M. of four experiments. B. Effect of 1 μM forskolin on PDGF- stimulated DNA synthesis. Results are
presented as mean ± S.E.M. of four experiments. C. Time-dependent effect of 1 μM PGE2 on cAMP accumulation in the absence of IBMX. Results are
from one typical of four experiments and are presented as mean ± S.E.M. of triplicates. D. Time-dependent effect of 5 μM forskolin on cAMP
accumulation in the absence of IBMX. Results are from one typical of four experiments and are presented as mean ± S.E.M. of triplicates. * Sign.
different from control. ** Sign. different from PDGF alone.
Pomianowska et al. BMC Cancer 2014, 14:413 Page 10 of 13
http://www.biomedcentral.com/1471-2407/14/413revealed no detectable COX-2 expression in the stroma –
neither in the normal pancreas nor in the pancreatic
cancer. In contrast Charo et al. [40] reported COX-2
expression in the stroma. One reason for the discrepancy
in the results could be the use of different antibodies. For
immunohistochemical staining in the study presented by
Charo [40] the polyclonal rabbit antihuman COX-2 anti-
body was used. It is known that polyclonal antibodies are
more sensitive, but do not show as high specificity, as
monoclonal antibodies [61]. To confirm the expression ofCo
lla
ge
n 
sy
nt
he
si
s, 
%
 o
f c
on
tr
ol
0
50
100
200
250
150
0
50
100
150
200
Co
lla
ge
n 
sy
nt
he
si
s, 
%
 o
f c
on
tr
ol
A. B.
*
Control TGFβ PDGF EGF
Figure 6 Effects of different agonists on collagen synthesis. A. Effect o
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tive for COX-2. The COX-2 staining was perinuclear andControl
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http://www.biomedcentral.com/1471-2407/14/413was constant in different passages (data not shown).
COX-2 expression could be further induced by stimu-
lating the stellate cells with IL-1β, EGF, thrombin, and
PGE2. Also, indirect coculture with the BxPC-3 cell
line, but not HPAFII or Panc-1 cells, induced COX-2
expression. Pretreatment of the stellate cells with IL-1
receptor antagonist blocked the induction of COX-2
induced by BxPC-3 cells, which is consistent with the fact
that the BxPC-3 cell line is known to produce IL-1α [64].
Interestingly, conditioned medium from Panc-1 cells in-
duced COX-2 in rat pancreatic stellate cells, however, how
this was mediated was not examined [51].
Conclusions
The present results show that COX-2 is mainly expressed
in carcinoma cells, and suggest that the cancer cells are
the main source of PGE2 in pancreatic tumours. In the
pancreatic stellate cells, PGE2 exerts both antiproliferativeand antifibrotic effects. These effects of PGE2 are medi-
ated by the cAMP pathway and suggests a role of EP2
receptors. Inhibition of COX-2 may inadvertently acceler-
ate fibrosis progression in pancreatic cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EP, DS, TC, IPG conceived and planned the study. EP and KG isolated the
pancreatic stellate cells. EP and DS did the cell culturing work. EP and ARS
did the immunohistochemistry and immunofluorescence work. DS, EP, IHT,
MA and VT conducted the experimental work. DS, EP and IPG analysed and
discussed the results. DS, EP and IPG drafted the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This study was supported by the Norwegian Cancer Society. We thank Ole
Petter F. Clausen for help with the immunohistochemistry work, Eva Østby
Magnussen for help with the collagen synthesis experiments, and John
Ødegård and Magne Bryne for help with the initial immunocytochemistry
work.
Pomianowska et al. BMC Cancer 2014, 14:413 Page 12 of 13
http://www.biomedcentral.com/1471-2407/14/413Author details
1Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo,
Norway. 2Department of Hepato-pancreato-biliary Surgery, Oslo University
Hospital, Rikshospitalet, PO Box 4956, Nydalen 0424 Oslo, Norway.
3Department of Pharmacology, Faculty of Medicine, University of Oslo and
Oslo University Hospital, Oslo, Norway. 4Department of Pathology, Oslo
University Hospital, Rikshospitalet, Oslo, Norway.
Received: 3 May 2013 Accepted: 20 May 2014
Published: 9 June 2014References
1. Krejs GJ: Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010,
28(2):355–358.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61(2):69–90.
3. Hidalgo M: Pancreatic cancer. N Engl J Med 2010, 362(17):1605–1617.
4. Chu GC, Kimmelman AC, Hezel AF, DePinho RA: Stromal biology of
pancreatic cancer. J Cell Biochem 2007, 101(4):887–907.
5. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA,
Buchler M, Friess H, McCarroll JA, Keogh G, Merrett N, Pirola R, Wilson JS:
Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate
cells. Pancreas 2004, 29(3):179–187.
6. Apte MV, Pirola RC, Wilson JS: Pancreatic stellate cells: a starring role in
normal and diseased pancreas. Front Physiol 2012, 3:344.
7. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D,
Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig
C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A,
Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani
SR, Huang P, Davies SE, Plunkett W, Egorin M, et al: Inhibition of hedgehog
signaling enhances delivery of chemotherapy in a mouse model of
pancreatic cancer. Science 2009, 324(5933):1457–1461.
8. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W,
Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O’Dwyer PJ, Vonderheide RH:
CD40 agonists alter tumor stroma and show efficacy against pancreatic
carcinoma in mice and humans. Science 2011, 331(6024):1612–1616.
9. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C,
Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A,
Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN,
Tuveson DA: Hyaluronan impairs vascular function and drug delivery in a
mouse model of pancreatic cancer. Gut 2013, 62(1):112–120.
10. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, Toi CS, Pirola RC,
Wilson JS, Goldstein D, Apte MV: Pancreatic stellate cells: partners in crime
with pancreatic cancer cells. Cancer Res 2008, 68(7):2085–2093.
11. Wang D, Dubois RN: Eicosanoids and cancer. Nat Rev Cancer 2010,
10(3):181–193.
12. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S,
Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Matsuura N, Nakamori
S, Monden M: Overexpression of cyclooxygenase-2 in carcinoma of the
pancreas. Clin Cancer Res 1999, 5(8):2018–2024.
13. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA,
Masferrer JL, Woerner BM, Koki AT, Fahey TJ III: Cyclooxygenase-2
expression is Up-regulated in human pancreatic cancer. Cancer Res 1999,
59(5):987–990.
14. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A,
Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ: Cyclooxygenase-2
expression in human pancreatic adenocarcinomas. Carcinogenesis 2000,
21(2):139–146.
15. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C: Cyclooxygenase-2
expression correlates with poor prognosis in pancreatic cancer. J Clin
Pathol 2006, 59(4):382–386.
16. Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R,
Visvanathan K, Goggins M: Tumor COX-2 expression and prognosis of
patients with resectable pancreatic cancer. Cancer Biol Ther 2007,
6(10):1569–1575.
17. Muller-Decker K, Furstenberger G, Annan N, Kucher D, Pohl-Arnold A,
Steinbauer B, Esposito I, Chiblak S, Friess H, Schirmacher P, Berger I:
Preinvasive duct-derived neoplasms in pancreas of keratin
5-promoter cyclooxygenase-2 transgenic mice. Gastroenterology
2006, 130(7):2165–2178.18. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK,
Pavone AI, Sawicki J, Fischer SM: Progressive metaplastic and dysplastic
changes in mouse pancreas induced by cyclooxygenase-2
overexpression. Neoplasia 2008, 10(8):782–796.
19. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD: Prostanoid receptors:
subtypes and signaling. Annu Rev Pharmacol Toxicol 2001, 41:661–690.
20. Sugimoto Y, Narumiya S: Prostaglandin E receptors. J Biol Chem 2007,
282(16):11613–11617.
21. Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW: EP1 prostanoid
receptor coupling to G I/o Up-regulates the expression of hypoxia-inducible
factor-1 alpha through activation of a phosphoinositide-3 kinase signaling
pathway. Mol Pharmacol 2010, 77(6):1025–1036.
22. Hirata T, Narumiya S: Prostanoid receptors. Chem Rev 2011,
111(10):6209–6230.
23. Yokoyama U, Patel HH, Lai NC, Aroonsakool N, Roth DM, Insel PA: The cyclic
AMP effector epac integrates Pro- and anti-fibrotic signals. Proc Natl Acad
Sci U S A 2008, 105(17):6386–6391.
24. Bozyk PD, Moore BB: Prostaglandin E2 and the pathogenesis of
pulmonary fibrosis. Am J Respir Cell Mol Biol 2011, 45(3):445–452.
25. Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, Snead A, Lu D,
Aroonsakool N: CAMP and Epac in the regulation of tissue fibrosis. Br J
Pharmacol 2012, 166(2):447–456.
26. White KE, Ding Q, Moore BB, Peters-Golden M, Ware LB, Matthay MA, Olman
MA: Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic
effects in acute lung injury through differential utilization of prostanoid
receptors. J Immunol 2008, 180(1):637–646.
27. Watanabe T, Satoh H, Togoh M, Taniguchi S, Hashimoto Y, Kurokawa K:
Positive and negative regulation of cell proliferation through prostaglandin
receptors in NIH-3 T3 cells. J Cell Physiol 1996, 169(2):401–409.
28. Oga T, Matsuoka T, Yao C, Nonomura K, Kitaoka S, Sakata D, Kita Y, Tanizawa
K, Taguchi Y, Chin K, Mishima M, Shimizu T, Narumiya S: Prostaglandin F
(2alpha) receptor signaling facilitates bleomycin-induced pulmonary
fibrosis independently of transforming growth factor-beta. Nat Med 2009,
15(12):1426–1430.
29. Harding P, LaPointe MC: Prostaglandin E2 increases cardiac fibroblast
proliferation and increases cyclin D expression Via EP1 receptor.
Prostaglandins Leukot Essent Fatty Acids 2011, 84(5–6):147–152.
30. Hui AY, Dannenberg AJ, Sung JJ, Subbaramaiah K, Du B, Olinga P, Friedman
SL: Prostaglandin E2 inhibits transforming growth factor beta 1-mediated
induction of collagen alpha 1(I) in hepatic stellate cells. J Hepatol 2004,
41(2):251–258.
31. Mallat A, Gallois C, Tao J, Habib A, Maclouf J, Mavier P, Preaux AM,
Lotersztajn S: Platelet-derived growth factor-BB and thrombin generate
positive and negative signals for human hepatic stellate cell
proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk
with endothelin receptors. J Biol Chem 1998, 273(42):27300–27305.
32. Koide S, Kobayashi Y, Oki Y, Nakamura H: Prostaglandin E2 inhibits
platelet-derived growth factor-stimulated cell proliferation through a
prostaglandin E receptor EP2 subtype in Rat hepatic stellate cells. Dig Dis
Sci 2004, 49(9):1394–1400.
33. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A,
Siech M, Beger H, Grunert A, Adler G: Identification, culture, and
characterization of pancreatic stellate cells in rats and humans.
Gastroenterology 1998, 115(2):421–432.
34. Refsnes M, Thoresen GH, Dajani OF, Christoffersen T: Stimulation of
hepatocyte DNA synthesis by prostaglandin E2 and prostaglandin F2
alpha: additivity with the effect of norepinephrine, and synergism with
epidermal growth factor. J Cell Physiol 1994, 159(1):35–40.
35. Jaster R, Hilgendorf I, Fitzner B, Brock P, Sparmann G, Emmrich J, Liebe S:
Regulation of pancreatic stellate cell function in vitro: biological and molecular
effects of all-trans retinoic acid. Biochem Pharmacol 2003, 66(4):633–641.
36. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL:
Primer-BLAST: a tool to design target-specific primers for polymerase
chain reaction. BMC Bioinforma 2012, 13:134.
37. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2 (−delta delta C (T)) method.
Methods 2001, 25(4):402–408.
38. Skomedal T, Grynne B, Osnes JB, Sjetnan AE, Oye I: A radioimmunoassay
for cyclic AMP (CAMP) obtained by acetylation of both unlabeled and
labeled (3H-CAMP) ligand, or of unlabeled ligand only. Acta Pharmacol
Toxicol (Copenh) 1980, 46(3):200–204.
Pomianowska et al. BMC Cancer 2014, 14:413 Page 13 of 13
http://www.biomedcentral.com/1471-2407/14/41339. Sato N, Maehara N, Goggins M: Gene expression profiling of tumor-stromal
interactions between pancreatic cancer cells and stromal fibroblasts. Cancer
Res 2004, 64(19):6950–6956.
40. Charo C, Holla V, Arumugam T, Hwang R, Yang P, Dubois RN, Menter DG,
Logsdon CD, Ramachandran V: Prostaglandin E2 regulates pancreatic
stellate cell activity Via the EP4 receptor. Pancreas 2013, 42(3):467–474.
41. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M:
Prostaglandin E (2) inhibits collagen expression and proliferation in
patient-derived normal lung fibroblasts Via E prostanoid 2 receptor and
CAMP signaling. Am J Physiol Lung Cell Mol Physiol 2007, 292(2):L405–L413.
42. Seamon KB, Padgett W, Daly JW: Forskolin: unique diterpene activator of
adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci
U S A 1981, 78(6):3363–3367.
43. Machwate M, Harada S, Leu CT, Seedor G, Labelle M, Gallant M, Hutchins S,
Lachance N, Sawyer N, Slipetz D, Metters KM, Rodan SB, Young R, Rodan
GA: Prostaglandin receptor EP (4) mediates the bone anabolic effects of
PGE(2). Mol Pharmacol 2001, 60(1):36–41.
44. Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou
S, Schmid-Kotsas A, Adler G: Pancreatic carcinoma cells induce fibrosis by
stimulating proliferation and matrix synthesis of stellate cells.
Gastroenterology 2005, 12847(4):907–921.
45. Luttenberger T, Schmid-Kotsas A, Menke A, Siech M, Beger H, Adler G, Grunert
A, Bachem MG: Platelet-derived growth factors stimulate proliferation and
extracellular matrix synthesis of pancreatic stellate cells: implications in
pathogenesis of pancreas fibrosis. Lab Invest 2000, 80(1):47–55.
46. Menke A, Adler G: TGFbeta-induced fibrogenesis of the pancreas. Int J
Gastrointest Cancer 2002, 31(1–3):41–46.
47. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M:
Cultured lung fibroblasts isolated from patients with idiopathic pulmonary
fibrosis have a diminished capacity to synthesize prostaglandin E2 and to
express cyclooxygenase-2. J Clin Invest 1995, 95(4):1861–1868.
48. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H,
Laurent GJ, Hart SL, Foster ML, McAnulty RJ: Cyclooxygenase-2 deficiency
results in a loss of the anti-proliferative response to transforming
growth factor-beta in human fibrotic lung fibroblasts and promotes
bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001,
158(4):1411–1422.
49. Handler JA, Danilowicz RM, Eling TE: Mitogenic signaling by epidermal
growth factor (EGF), but Not platelet-derived growth factor, requires
arachidonic acid metabolism in BALB/c 3 T3 cells. Modulation of
EGF-dependent C-Myc expression by prostaglandins. J Biol Chem 1990,
265(7):3669–3673.
50. Castano E, Bartrons R, Gil J: Inhibition of cyclooxygenase-2 decreases DNA
synthesis induced by platelet-derived growth factor in Swiss 3 T3
fibroblasts. J Pharmacol Exp Ther 2000, 293(2):509–513.
51. Yoshida S, Ujiki M, Ding XZ, Pelham C, Talamonti MS, Bell RH Jr, Denham W,
Adrian TE: Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2)
and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer 2005, 4(1):27.
52. Smith ML, Hawcroft G, Hull MA: The effect of Non-steroidal anti-inflammatory
drugs on human colorectal cancer cells: evidence of different mechanisms of
action. Eur J Cancer 2000, 36(5):664–674.
53. Denkert C, Furstenberg A, Daniel PT, Koch I, Kobel M, Weichert W, Siegert A,
Hauptmann S: Induction of G0/G1 cell cycle arrest in ovarian carcinoma
cells by the anti-inflammatory drug NS-398, but Not by COX-2-specific
RNA interference. Oncogene 2003, 22(54):8653–8661.
54. Elder DJ, Halton DE, Hague A, Paraskeva C: Induction of apoptotic cell
death in human colorectal carcinoma cell lines by a cyclooxygenase-2
(COX-2)-selective nonsteroidal anti-inflammatory drug: independence
from COX-2 protein expression. Clin Cancer Res 1997, 3(10):1679–1683.
55. Black SA Jr, Palamakumbura AH, Stan M, Trackman PC: Tissue-specific
mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions
between CAMP and MAPK signaling pathways, and prostaglandin
E2-EP3 receptor mediated activation of the C-JUN N-terminal kinase.
J Biol Chem 2007, 282(21):15416–15429.
56. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yoshida
S: Increased expression of cyclooxygenase-2 in human pancreatic
neoplasms and potential for chemoprevention by cyclooxygenase
inhibitors. Cancer 2001, 91(2):333–338.
57. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, Rhee JC: Role of
cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic
cancer. J Gastroenterol Hepatol 2002, 17(8):914–921.58. Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S,
Nakajima S, Doi R, Imamura M: Immunohistochemical analysis of
cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999,
26(2):69–76.
59. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA: Increased
cyclooxygenase-2 expression in human pancreatic carcinomas and cell
lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer
Res 1999, 59(17):4356–4362.
60. Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, Beger HG:
Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002,
25(1):26–30.
61. Saukkonen K, Nieminen O, Van RB, Vilkki S, Harkonen M, Juhola M, Mecklin
JP, Sipponen P, Ristimaki A: Expression of cyclooxygenase-2 in dysplasia
of the stomach and in intestinal-type gastric adenocarcinoma. Clin
Cancer Res 2001, 7(7):1923–1931.
62. Vonlaufen A, Phillips PA, Yang L, Xu Z, Fiala-Beer E, Zhang X, Pirola RC, Wilson
JS, Apte MV: Isolation of quiescent human pancreatic stellate cells: a
promising in vitro tool for studies of human pancreatic stellate cell biology.
Pancreatology 2010, 10(4):434–443.
63. Aoki H, Ohnishi H, Hama K, Shinozaki S, Kita H, Osawa H, Yamamoto H, Sato
K, Tamada K, Sugano K: Cyclooxygenase-2 is required for activated
pancreatic stellate cells to respond to proinflammatory cytokines. Am J
Physiol Cell Physiol 2007, 292(1):C259–C268.
64. Xu D, Matsuo Y, Ma J, Koide S, Ochi N, Yasuda A, Funahashi H, Okada Y,
Takeyama H: Cancer cell-derived IL-1alpha promotes HGF secretion by
stromal cells and enhances metastatic potential in pancreatic cancer
cells. J Surg Oncol 2010, 102(5):469–477.
doi:10.1186/1471-2407-14-413
Cite this article as: Pomianowska et al.: Inhibitory effects of
prostaglandin E2 on collagen synthesis and cell proliferation in human
stellate cells from pancreatic head adenocarcinoma. BMC Cancer
2014 14:413.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
